Antibiotics Business Drives Lukang Pharma's Profitability Boost
This article was originally published in PharmAsia News
Lukang Pharmaceutical recently reported first quarter profits of RMB 47.27 million, up 855 percent, due mostly to substantial growth in its antibiotics business
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.